CAR-T Therapy: Approach to Bridging
Panelists explain how CAR-T cell therapy works and describe the treatment process, discussing whether CAR -T is considered a complex procedure at their institution or if the logistics have been streamlined into clinical workflows, and they also detail their institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion, including whether patients are managed in-house or sent back to community centers.
Video content above is prompted by the following:
- Could you explain how CAR-T cell therapy works and describe the treatment process?
- Do you consider CAR-T therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Can you explain your institution's approach to bridging therapy for patients awaiting CAR-T manufacturing and infusion?
- Do you send patients back to community centers or is does it the treatment happen done in-house?
Fostering Academic, Community Practice Collaboration for Bispecific Therapy in Multiple Myeloma
December 26th 2024Experts in multiple myeloma spoke about optimal treatment strategies for patients who receive bispecific therapy, focusing specifically on facilitating a multifaceted approach between academic and community practices.
